Algal Toxins as Guidance to Identify Phosphoproteins with Key Roles inApoptotic Cell Death
The protein phosphatase inhibiting toxins microcystin and nodularin act rapidly to induce apoptotic cell death.Their inhibitory effect on protein phosphatases 1 and 2A can be utilized as tools to understand the phosphorylation-dependent regulatory mechanism underlying the early stage of apoptosis. The incubation of freshly isolated hepatocyteswith these toxins results in a rapid hyperphosphorylation of cellular proteins before any morphological signs of apoptosisappears [Fladmark, K. E., Brustugun, O. T., Hovland, R., Boe, R., Gjertsen, B. T., Zhivotovsky, B. and Doskeland, S. O.(1999) Cell Death Differ. 6, 1099-108]. Proteins subjected to phosphorylation in this early phase of apoptosis may playkey roles in this cellular process and become valuable targets for drug development. The ultra-rapid apoptosis-inductionby microcystin and nodularin provides a unique amount of synchronized apoptotic cells with "large" amounts of mainlyserine/threonine phosphorylated proteins. This ultra-rapid toxin-induced up-concentration of phosphorylated proteins re-duces the material needed as well as simplifies our effort in order to obtain enough phosphoproteins for mass spectromet-ric identification and characterization. We will here give an overview of our strategy for identification of low-abundancephosphoproteins involved in algal toxin-induced apoptosis and most likely also in a general apoptotic pathway.
Keywords: Phosphatase inhibitor; apoptosis; massspectrometry; microcystin; nodularin; phosphopeptide enrichment; phosphorylation
Document Type: Research Article
Affiliations: Proteomic Unit, Dept. ofBiomedicine,University of Bergen. Jonas Lies vei 91, N-5009, Norway.
Publication date: 01 June 2006
- Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content